Alnylam Pharmaceuticals (ALNY) Other financing activities (2009 - 2026)

Alnylam Pharmaceuticals' Other financing activities history runs 18 years deep, the most recent figure standing at -$9000.0 for Q1 2026.

• Quarterly Other financing activities changed N/A year-over-year to -$9000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $250.0 million (down 9.77% YoY) and the FY2025 annual result came in at $250.0 million, down 17.47% from the prior year.
• Other financing activities was -$9000.0 for Q1 2026 at Alnylam Pharmaceuticals, down from $41.7 million in the prior quarter.
• Across five years, Other financing activities topped out at $235.9 million in Q4 2022 and bottomed at -$9000.0 in Q1 2026.
• A 5-year average of $60.0 million and a median of $39.0 million in 2024 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2022 — Other financing activities plunged 96.22% — and 2023, when it soared 530.51%.
• Alnylam Pharmaceuticals' Other financing activities stood at $235.9 million in 2022, then plunged by 86.9% to $30.9 million in 2023, then rose by 17.43% to $36.3 million in 2024, then gained by 14.95% to $41.7 million in 2025, then tumbled by 100.02% to -$9000.0 in 2026.
• Business Quant data shows ALNY's Other financing activities at -$9000.0 in Q1 2026, $41.7 million in Q4 2025, and $77.7 million in Q3 2025.